Nephroplan (Magnesium Carbonate Heavy, Calcium Acetate)

Magnesium carbonate, Calcium acetate, the active ingredients in Nephroplan, are phosphate binders presented as an oral formulation for oral administration. They are prescribed to lower elevated serum phosphate concentrations in patients with chronic kidney disease, thereby assisting in the management of hyperphosphatemia and reducing the risk of mineral‑bone complications.

GNH USA supplies Nephroplan as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide while adhering to EU quality standards and reliable.

Nephroplan is a phosphate binder used to manage disorders of phosphate metabolism in chronic kidney disease. - Hyperphosphatemia: reduces serum phosphate levels in CKD patients. - Chronic kidney disease‑related mineral bone disorder: helps control phosphate load contributing to bone disease. - End‑stage renal disease (ESRD) patients on dialysis: assists in maintaining target phosphate concentrations.

Nephroplan may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate discomfort in the stomach. - Constipation: reduced bowel movements, often manageable with diet. - Abdominal discomfort: cramping or bloating. - Flatulence: increased gas production. - Diarrhea: loose stools in some patients. - Taste alteration: temporary change in flavor perception.

Serious or Rare Side Effects: - Hypercalcemia: elevated calcium levels requiring medical attention. - Metabolic alkalosis: disturbance in blood pH balance. - Severe constipation leading to bowel obstruction. - Allergic reactions: rash, itching, or anaphylaxis in rare cases. - Significant electrolyte imbalance: abnormal levels of magnesium or calcium. - Severe abdominal pain: may indicate complications requiring evaluation.

When prescribing Nephroplan, clinicians should consider several precautionary measures to ensure safe use. - Monitor serum phosphate: adjust dose based on regular laboratory results. - Assess calcium balance: watch for signs of hypercalcemia, especially with calcium‑containing diets. - Evaluate bowel function: avoid use in patients with active bowel obstruction. - Caution in severe hypercalcemia: contraindicated in patients with markedly elevated calcium levels. - Adjust for renal function: dose may need modification in severe renal impairment. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Nephroplan can interact with other medicines, affecting its phosphate‑binding capacity or causing additive effects.

Major Interactions (Avoid): - Aluminum‑containing antacids: may reduce phosphate binding efficiency. - Calcium supplements: increase total calcium load, raising hypercalcemia risk. - Iron supplements: can interfere with binder activity and reduce absorption.

Moderate Interactions (Monitor Closely): - Vitamin D analogues: may amplify calcium and phosphate changes. - ACE inhibitors: potential additive effects on electrolyte balance. - Loop diuretics: influence calcium excretion, requiring monitoring.